Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

CNBC - 29 Jul 2025 13:02
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.
Full Article at CNBC

More Market News
0
0
0


Storyboard
Print
Share this Article



Comment on this Article

Please Sign In to comment

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard